Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
Your view on PBYI
Overview
What the company does, where it operates, and who runs it.
About Puma Biotechnology, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alan H. Auerbach
- Headquarters
- 10880 Wilshire Boulevard, Los Angeles, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alan H. Auerbach
- Headquarters
- 10880 Wilshire Boulevard, Los Angeles, CA, US
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.
It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Puma Biotechnology, Inc., and the rating behind it. PBYI last traded at $9.12, 16.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Puma Biotechnology, Inc.. Starting points for Puma Biotechnology, Inc.: P/E 16.9, EPS $0.52, beta 1.23 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Puma Biotechnology, Inc.. Puma Biotechnology, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Puma Biotechnology, Inc.. Trailing twelve-month EPS for Puma Biotechnology, Inc. stands at $0.52. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Puma Biotechnology, Inc.. Puma Biotechnology, Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Puma Biotechnology, Inc. valued side by side against its closest peers. Puma Biotechnology, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Puma Biotechnology, Inc., and how their positions are changing. At a $464.2M market value, institutional positions materially move Puma Biotechnology, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Puma Biotechnology, Inc. executives and directors. Shares of Puma Biotechnology, Inc. have traded between $2.58 and $6.12 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Puma Biotechnology, Inc.. Puma Biotechnology, Inc. is a $464.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Puma Biotechnology, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Puma Biotechnology, Inc.. Coverage tracks Puma Biotechnology, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.